Top

Published in:

Open Access 01-06-2014 | Review

Single-Tablet Regimens in HIV Therapy

Authors: Noemi Astuti, Franco Maggiolo

Published in: Infectious Diseases and Therapy | Issue 1/2014

Abstract

Combined antiretroviral therapy (cART) has evolved considerably over the past decades leading to a better control of human immunodeficiency virus replication. Recently, regimens have evolved so as to simplify dosing frequency and reduce pill burden to improve adherence. Several national and international guidelines suggest antiretroviral (ARV) regimen simplification as a method of improving adherence. Decreased cART adherence has been associated with both patient-related factors and regimen-related factors. Adherence rates are statistically higher when simpler, once-daily (OD) regimens are combined with smaller daily regimen pill burdens. The avoidance of selective non-adherence, where a patient takes part of a regimen but not the full regimen, is a further potential benefit offered by single-tablet regimens (STRs). Simplification of cART has been associated with a better quality of life (QoL). Although tempered by other factors, better adherence, higher QoL and patients’ preferences are all key points which might combine to assure long-lasting efficacy and durability of cART. All studies underlined the favorable tolerability profile of newer STRs. Three STRs are currently available. Tenofovir (TDF) plus emtricitabine (FTC)/efavirenz (EFV) was the first OD complete ARV regimen available as a STR. TDF plus FTC/rilpivirine is a second-generation STR. The most recently approved STR, TDF plus FTC/cobicistat/elvitegravir, is the first non-nucleoside reverse transcriptase inhibitor-based STR. All of them have shown excellent efficacy; safety and tolerability have been improved by more recent formulations. Several other STRs are anticipated both combining completely different drugs, abacavir (ABC) plus lamivudine (3TC)/dolutegravir, utilizing innovative formulations of older drugs, tenofovir alafenamide fumarate, or taking advance of bioequivalent drugs, lamivudine (3TC) plus ABC/EFV. The future challenge would be to develop completely alternative STRs (including for example protease inhibitors or new molecules) to extend the advantages of simplicity to heavily pre-treated individuals.

Available only for authorised users

Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354(3): 251–260.

Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817–33.PubMedCentralPubMedCrossRef

Blasco AJ, Arribas JR, Boix V, et al. Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012. Enferm Infecc Microbiol Clin. 2012;30(6):283–93.PubMedCrossRef

Antinori A, Marcotullio S, Ammassari A, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol. 2011;34(2):109–46.PubMed

Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once daily fixed-dose combination antiretroviral therapy. AIDS. 2008;22(15):1951–60.PubMedCentralPubMedCrossRef

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services, December 1, 2009. http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0. Accessed Dec 2013.

Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.PubMedCrossRef

Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. JAIDS. 2004;36(3):808–16.PubMed

Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4):169–77.PubMedCrossRef

10.

Ickovics JR, Meade CS. Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. JAIDS. 2002;31(Suppl 3):S98–102.PubMed

11.

Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naïve individuals initiating HAART is specific to individual drug classes. JAIDS. 2008;49(3):266–71.

12.

Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24(18):2835–40.PubMedCentralPubMedCrossRef

13.

Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8(5):282–92.PubMedCrossRef

14.

Aragão F, Vera J, Vaz Pinto I. Cost effectiveness of third agent class in treatment-naïve human immunodeficiency virus-infected patients in Portugal. PLOS one. 2012;7(9):e44774.

15.

Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3:371–8.PubMedCrossRef

16.

DeJesus E, Ruane P, McDonald C, et al. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixeddose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials. 2008;9(2):103–14.PubMedCrossRef

17.

Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40(1):158–63.PubMedCrossRef

18.

Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: selfreport of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. AIDS. 2004;36(3):808–16.

19.

Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48(4):484–8.PubMedCentralPubMedCrossRef

20.

De Jesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. JAIDS. 2009;51(2):163–74.

21.

Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adher. 2010;4:115–25.

22.

Juday T, Gupta S, Grimm K, Wagner S, Kim E. Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clin Trials. 2011;12(2):71–8.PubMedCrossRef

23.

Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilization and costs in a US medicaid population with HIV. BMJ Open. 2013;3:e003028.PubMedCentralPubMedCrossRef

24.

Vera J, Aragão F, Guimarães M, Vaz Pinto I. Benefit of HAART simplification on adherence, clinical and economic outcomes. In: HIV11, Glasgow UK, November 2012. Abstract P5. http://hivarchive.com/hiv11/uploads/Adherence%20-%20Part%20One.pdf. Accessed Dec 2013.

25.

Taneja C, Juday T, Gertzog L, et al. Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens. Expert Opin Pharmacother. 2012;13(15):2111–8.PubMedCrossRef

26.

Cohen C, Davis K, Meyers J. Association of partial adherence to antiretroviral therapy with hospitalizations and healthcare costs in an HIV population. JIAS. 2012;15(suppl. 4):18060.

27.

Antinori A, Angeletti C, Ammassari A, et al. Adherence in HIV-positive patients treated with single-tablet regimens and multi-pill regimens: findings from the COMPACT study. In: HIV11, Glasgow UK, November 2012. Abstract P145. http://www.jiasociety.org/index.php/jias/article/view/18433. Accessed Dec 2013.

28.

Laurence J. Treating HIV infection with one pill per day. AIDS Patient Care STDs. 2006;20(9):601–3.PubMedCrossRef

29.

Glass TR, De Geest S, Weber R, et al. Correlates of self-reported non-adherence to antiretroviral therapy in HIV-infected patients. The Swiss HIV Cohort study. JAIDS. 2006;41(3):385–92.PubMed

30.

Deschamps AE, De Graeve V, Van Wijngaerden E, et al. Prevalence and correlates of non adherence to antiretroviral therapy in a population of HIV patients using medication event monitoring system. AIDS Patient Care STDs. 2004;18(11):644–57.PubMedCrossRef

31.

Heath KV, Singer J, O’Shaughnessy MV, et al. Intentional non adherence due to adverse symptoms associate with antiretroviral therapy. JAIDS. 2002;31(2):211–7.PubMed

32.

Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. JAIDS. 2002;31:S140–4.PubMed

33.

Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. JAIDS. 2008;47(3):384–90.PubMed

34.

Homar F, Lozano V, Martínez-Gómez J, et al. Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs. Health Econ Rev. 2012;2(1):16 (Epub ahead of print).

35.

Juday T, Grimm K, Willig J, Zoe-Powers A, Kim E. A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. AIDS Care. 2011;23(9):1154–62.PubMedCentralPubMedCrossRef

36.

Hodder SL, Mounzer K, Dejesus E, et al. Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDs. 2010;24(2):87–96.PubMedCrossRef

37.

Palella F, Tebas P, Gazzard B, et al. SPIRIT study: switching boosted PI to rilpivirine in combination with truvada as a single tablet regimen. In: International AIDS conference, Washington DC, July 2012. Abstract TUAB0104. http://www.natap.org/2012/IAS/IAS_05.htm. Accessed Dec 2013.

38.

Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS ONE. 2012;7(2):e31591.PubMedCentralPubMedCrossRef

39.

Colombo GL, Di Matteo S, Maggiolo F, et al. Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the Single Tablet Regimen (STR). Clinicoecon Outcomes Res. 2013;5:59–68.PubMedCentralPubMedCrossRef

40.

German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. JAIDS. 2010;55(3):323–9.PubMed

41.

Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011;25(6):F7–12.PubMedCrossRef

42.

Elion R, Gathe J, Rashbaum B, et al. The single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; “QUAD”) maintains a high rate of virologic suppression, and cobicistat (COBI) is an effective pharmacoenhancer through 48 weeks. In: 50th ICAAC 2010, Boston, USA. Abstract PH-938-B. http://www.hivandhepatitis.com/2010_conference/icaac/posters/Quad.pdf. Accessed Dec 2013.

43.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services; December 2013. http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0. Accessed Jan 2014.

44.

European AIDS Clinical Society. Guidelines for the Clinical management and Treatment of HIV Infected Adults in Europe. Version 7.0, Oct 2013. http://www.eacsociety.org/Guidelines.aspx. Accessed Jan 2014.

45.

Antinori A, Marcotullio S, Ammassari A, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons (November 2013). http://www.salute.gov.it/imgs/C_17_pubblicazioni_1793_allegato.pdf. Accessed Jan 2014.

46.

Moyle G, Orkin C, Fisher M, et al. Switching to a single-tablet regimen (STR) of Atripla^®(ATR) from a 2 or 3-pill combination of the individual components (efavirenz [EFV], emtricitabine[FTC] and tenofovir df [TDF]) maintains virological suppression: primary endpoint results of a 48-week, open-label study. HIV Med. 2011;12:79.

47.

Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla^®): a review of its use in the management of HIV infection. Drugs. 2010;70(17):2315–38.PubMedCrossRef

48.

De Jesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomized, double blind, phase 3, non-inferiority trial. Lancet. 2012;379:2429–38.CrossRef

49.

Rockstroh JK, De Jesus E, Henry K, et al. A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. JAIDS. 2013;62(5):483–6.PubMed

50.

Charpentier C, Lambert-Niclot S, Visseaux B, et al. Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010. JAC. 201;68(10):2197–8.

51.

Ortega-Gonzales E, Garcia Deltoro M, Lopez-AldeguerJ, et al. Trend and prevalence of HIV-1 resistance mutations in the Valencian Autonomous Region (2004–2011) and its relation with the antiretroviral usage pattern: RUVEN study (SEICV-VIH-2012-01). In: 14th EACS, Brussels Belgium, October 2013. Abstract PE9/28. http://www.abstracttosubmit.com/eacs2013/eposter/. Accessed Feb 2014.

52.

Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine versus efavirenz at 48 weeks in treatment-naïve HIV-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. JAIDS. 2012;60(1):33–42.PubMed

53.

Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2013;16 [Epub ahead of print].

54.

Eron J, Rockstroh J, Pozniak A, et al. Dolutegravir treatment response by baseline viral load and NRTI backbone in treatment-naïve HIV-infected individuals. In: HIV11, Glasgow UK, November 2012. Abstract P204. http://www.natap.org/2012/interHIV/InterHIV_03.htm. Accessed Dec 2013.

55.

Raffi F, Jaeger H, Quiros-Roldan E, et al. Once daily dolutegravir versus twice daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study):96 week results from a randomized, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–35.PubMedCrossRef

56.

Feinberg J, Clotet B, Khuong MA, et al. Once-daily dolutegravir is superior to darunavir/ritonavir in antiretroviral naive adults: 48 week results from Flamingo. In: 53rd ICAAC, Denver USA, September 2013. Abstract H1464a. http://www.natap.org/2013/ICAAC/ICAAC_24.htm. Accessed Dec 2013.

57.

Cohen C, Wohl D, Arribas J et al. STaR study: single tablet regimen emtricitabine/rilpivirine/tenofovir is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adults. In: HIV11, Glasgow UK, November 2012. Abstract O425. http://www.jiasociety.org/index.php/jias/article/view/18221. Accessed Dec 2013.

58.

Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27(6):939–50.PubMedCrossRef

59.

Nelson M, Winston A, Waters L, et al. Multicentre open-label study of switching from atripla to eviplera for possible efavirenz associated CNS toxicity. In: 53rd ICAAC, Denver USA, September 2013. Abstract H-672-b. http://www.natap.org/2013/ICAAC/ICAAC_47.htm. Accessed Dec 2013.

60.

Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials. 2013;14(5):2216–355.CrossRef

61.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendation on integrase inhibitor use in antiretroviral treatment-naïve HIV-infected individuals from HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Department of Health and Human Services; October 30, 2013. http://aidsinfo.nih.gov/contentfiles/upload/adultARV_INSTIRecommendations.pdf. Accessed Jan 2014.

62.

Molina JM, Lamarca A, Andrade-Villanueva J, et al. International, randomized, double blinded, 96-week, non-inferiority study of EVG QD versus RAL BID in ARV-experienced patients. Lancet Infect Dis. 2012;12(1):27–35.PubMedCrossRef

63.

Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700–8.PubMedCrossRef

64.

Sax PE, De Jesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomized, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439–48.PubMedCrossRef

65.

Zolopa A, Sax PE, DeJesus E, et al. A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. JAIDS. 2013;63(1):96–100.PubMed

66.

Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–18.PubMedCrossRef

67.

Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. JAIDS. 2013;19 [Epub ahead of print].

68.

A study to determine safety and efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) in human immunodeficiency virus (HIV)-1 infected antiretroviral therapy (ART) Naïve women (ARIA). http://clinicaltrials.gov/show/NCT01910402?order=0. Accessed Jan 2014.

69.

Zolopa A, Ortiz R, Sax P, et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate, each with elvitegravir, cobicistat and emtricitabine for HIV treatment. In: 20th CROI, Atlanta USA, March 2013. Abstract 99LB. http://www.natap.org/2013/CROI/croi_23.htm. Accessed Dec 2013.

70.

Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449–55.PubMedCrossRef

71.

King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS. 2008;22:1709–17.PubMedCrossRef

72.

Schmidt D, Kollan C, Fatkenheuer G et al. Proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany. In: 14th European AIDS conference. Brussels, Belgium, October 2013. PE9/11. http://www.eacs-conference2013.com/fileadmin/templates/eacs/template_FILES/FINAL_EACS13_Final_Program_web.pdf. Accessed Dec 2013.

73.

Batmeyer B, Kuecherer C, Houareau C, et al. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 seroconverter cohort. PLoS ONE. 2010;5(10):e12718.CrossRef

74.

Meixenberger K, Scheufele R, Jansen K, et al. In vivo prevalence of transmitted drug-resistant HIV in patients with a known date of HIV-1 seroconversion. In: 14th European AIDS conference. Brussels, Belgium, October 2013. PE9/24. http://www.eacs-conference2013.com/fileadmin/templates/eacs/template_FILES/FINAL_EACS13_Final_Program_web.pdf. Accessed Dec 2013.

75.

Chueca N, Camacho-Luque R, Martinez NM, et al. Prevalence of low abundant rilpivirine resistance associated mutations in naïve patients from the south of Spain. In: 14th European AIDS Conference. Brussels, Belgium, October 2013. PE9/16. http://www.eacs-conference2013.com/fileadmin/templates/eacs/template_FILES/FINAL_EACS13_Final_Program_web.pdf. Accessed Dec 2013.

76.

Crauwels H, van Heeswijk RP, Stevens M, et al. Clinical perspective on drug–drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15(2):87–101.PubMed

77.

Sha BM, Schafer JJ, DeSimone JA. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy. 2013;18 [Epub ahead of print].

78.

Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013;30:613–28.PubMedCentralPubMedCrossRef

79.

NHS England Clinical Reference Group. Clinical Commissioning policy statement: stribild for the treatment of HIV-1 infection in adults. http://www.england.nhs.uk/wp-content/uploads/2013/09/b06-psa1.pdf. Accessed Jan 2014.

Title: Single-Tablet Regimens in HIV Therapy
Authors: Noemi Astuti
Franco Maggiolo
Publication date: 01-06-2014
Publisher: Springer Healthcare
Published in: Infectious Diseases and Therapy / Issue 1/2014
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI: https://doi.org/10.1007/s40121-014-0024-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Impact of a Multidisciplinary Culture Follow-up Program of Antimicrobial Therapy in the Emergency Department

Observation of “Seesaw Effect” with Vancomycin, Teicoplanin, Daptomycin and Ceftaroline in 150 Unique MRSA Strains

Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization

Erratum to: Epidemiology of Pneumococcal Disease in a National Cohort of Older Adults

Epidemiology of Pneumococcal Disease in a National Cohort of Older Adults

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials